» Articles » PMID: 26825094

Increased Epileptiform EEG Activity and Decreased Seizure Threshold in Arctic APP Transgenic Mouse Model of Alzheimer's Disease

Overview
Specialty Neurology
Date 2016 Jan 31
PMID 26825094
Citations 21
Authors
Affiliations
Soon will be listed here.
Abstract

Several Alzheimer model mice carrying transgenic amyloid precursor protein (APP) with the Swedish mutation have been reported to exhibit spontaneous seizures and/or increased epileptiform EEG activity. The primary cause for the epilepsy phenotype is still under debate. In contrast to mice with APPswe mutation that develop extracellular amyloid plaques, mice with APP Arctic mutation (E693G) have no bias toward β-secretase cleavage and display intracellular amyloid deposits but not plaques. We conducted a systematic long-term video-EEG recording in three two-week sessions on 21 APParc and 11 wild-type control mice between 3.5 and 8 months of age. Spontaneous seizures were not detected more often in APParc mice than in their wild-type control mice. Long (1 - 5 s) epileptiform discharges were occasionally detected in both APParc and wild-type mice, but short (0.5 - <1 s) epileptiform discharges were more common in APParc mice than in wild-types. However, they were far less frequent than in 6 APPswe/PS1dE9 mice recorded in parallel. In pentylenetetrazole test for seizure susceptibility, APParc mice displayed a shorter latency to sharp-wave discharges than wildtype mice but no increase in seizure duration. These data speak for a relatively mild epilepsy phenotype in APParc mice compared to APPswe mice despite even higher extent of APP overexpression. Thus extracellular amyloid plaques or increased β-secretase cleavage products appear important for the epilepsy phenotype in APPswe mice.

Citing Articles

Insulin signaling disruption exacerbates memory impairment and seizure susceptibility in an epilepsy model with Alzheimer's disease-like pathology.

Alves S, Servilha-Menezes G, Rossi L, Cortes de Oliveira J, Grigorio-de-SantAna M, Sebollela A J Neural Transm (Vienna). 2025; .

PMID: 39987343 DOI: 10.1007/s00702-025-02896-1.


Alzheimer's disease-associated genotypes differentially influence chronic evoked seizure outcomes and antiseizure medicine activity in aged mice.

Knox K, Davidson S, Lehmann L, Skinner E, Lo A, Jayadev S bioRxiv. 2024; .

PMID: 39416203 PMC: 11482912. DOI: 10.1101/2024.10.06.616921.


Innovative drug discovery strategies in epilepsy: integrating next-generation syndrome-specific mouse models to address pharmacoresistance and epileptogenesis.

Barker-Haliski M, Hawkins N Expert Opin Drug Discov. 2024; 19(9):1099-1113.

PMID: 39075876 PMC: 11390315. DOI: 10.1080/17460441.2024.2384455.


Latest advances in mechanisms of epileptic activity in Alzheimer's disease and dementia with Lewy Bodies.

Vicente M, Addo-Osafo K, Vossel K Front Neurol. 2024; 15:1277613.

PMID: 38390593 PMC: 10882721. DOI: 10.3389/fneur.2024.1277613.


Loss of normal Alzheimer's disease-associated Presenilin 2 function alters antiseizure medicine potency and tolerability in the 6-Hz focal seizure model.

Lehmann L, Barker-Haliski M Front Neurol. 2023; 14:1223472.

PMID: 37592944 PMC: 10427874. DOI: 10.3389/fneur.2023.1223472.